LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Rapid Extraction-Less COVID-19 Diagnostic Assay Detects SARS-CoV-2 in 30 Minutes

By LabMedica International staff writers
Posted on 29 Apr 2022
Image: CovidDetect RT-LAMP based detection assay for all known strains of SARS-CoV-2 (Photo courtesy of Prime Discoveries)
Image: CovidDetect RT-LAMP based detection assay for all known strains of SARS-CoV-2 (Photo courtesy of Prime Discoveries)

A rapid isothermal amplification diagnostic assay for detecting SARS-CoV-2 eliminates the need for RNA extraction and purification, with the sample result occurring in less than 30 minutes.

Prime Discoveries (New York, NY, USA) has developed CovidDetect, a rapid, specific, extraction-less, and cost-effective RT-LAMP test for the detection of SARS-CoV-2 in clinical specimens. The assay uses Mawi DNA Technologies’ (Hayward, CA, USA) new iSWAB Microbiome-EL (Extraction-Less) sample collection technology. This allows RNA release from the sample and maintains stability, protecting it from degradation and allowing room temperature storage and transport. CovidDetect leverages Mawi’s unique iSWAB Microbiome-EL sample collection buffer with Prime’s patented Loop AMPlification (LAMP) technology. This allows isothermal nucleic acid amplification removing the need for expensive thermal cycling equipment required for PCR. The extraction-less protocol bypasses the expensive and complex nucleic acid extraction and purification step, saving 60-90 minutes of sample processing time needed for PCR.

Prime has received CE IVD marking for CovidDetect and plans to pursue FDA 510K approval soon. The CE marking will allow the deployment of CovidDetect to countries in Africa and Asia where rapid, inexpensive diagnostics for various infections with minimal technical expertise and equipment infrastructure is highly required.

“The COVID pandemic has shown that there is a big need for rapid diagnostic assays. Prime Discoveries aims to build a portfolio of solutions which can provide results in under 45 minutes with minimal laboratory, reagent and technical skill requirements. This is ideal for point of care testing in rural neighborhoods, mobile testing, border points of entry and clinical locations with minimal infrastructure,” said Arun Manoharan, Ph.D., Chief Science Officer at Prime Discoveries. “Our work with COVID has shown stable performance of the Mawi iSWAB Microbiome-EL for hundreds of clinical samples with similar or superior performance to RT-PCR solutions. Samples have been stable for more than two weeks with minimal RNA degradation along with high compatibility with our isothermal nucleic acid amplification techniques.”

“Our partnership with Mawi enables Prime Discoveries to develop room temperature sampling with Extraction-Less capabilities for our rapid diagnostic solutions in many areas. These include influenza, chlamydia, gonorrhea, trichomonas, HBV, HCV, HPV, TB, herpes, syphilis, etc.,” added Manoharan “We are excited to partner with Mawi for future products empowering customers to test thousands of patients rapidly for various infections including respiratory, gastrointestinal, sexually transmitted pathogens and those with anti-microbial resistance.”

Related Links:
Mawi DNA Technologies 
Prime Discoveries 

Gold Member
SARS-CoV-2 Reactive & Non-Reactive Controls
Qnostics SARS-CoV-2 Typing
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gel Cards
DG Gel Cards
Gold Member
Immunochromatographic Assay
CRYPTO Cassette

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more